MA69210B1 - Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinine - Google Patents
Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinineInfo
- Publication number
- MA69210B1 MA69210B1 MA69210A MA69210A MA69210B1 MA 69210 B1 MA69210 B1 MA 69210B1 MA 69210 A MA69210 A MA 69210A MA 69210 A MA69210 A MA 69210A MA 69210 B1 MA69210 B1 MA 69210B1
- Authority
- MA
- Morocco
- Prior art keywords
- bradykinin
- matrix
- methyl
- receptor antagonists
- release composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne des comprimés pharmaceutiques matriciels pour administration orale comprenant un antagoniste du récepteur B2 de la bradykinine ayant une structure chimique selon la Formule (1), ou un sel ou un solvate de celui-ci, où R est le deutérium ou l'hydrogène : Formule (1) telle que (S)-lV-(l-deutéro-l-(3-chloro-5-fluoro-2-((2-méthyl-4-(l-méthyl-l//-l,2,4-triazol-5- yl)quinoline-8-yloxy)méthyl)phényl)éthyl)-2-(difluorométhoxy)acétamide. Les comprimés matriciels assurent de manière fiable une libération prolongée de l'antagoniste du récepteur B2 de la bradykinine, ce qui les rend particulièrement appropriés pour des thérapies prophylactiques et/ou chroniques. L'invention concerne également des utilisations thérapeutiques des comprimés matriciels.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164471 | 2022-03-25 | ||
| PCT/EP2023/057792 WO2023180576A1 (fr) | 2022-03-25 | 2023-03-27 | Composition solide à libération prolongée comprenant des antagonistes du récepteur b2 de la bradykinine |
| EP23715488.5A EP4499039B1 (fr) | 2022-03-25 | 2023-03-27 | Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA69210B1 true MA69210B1 (fr) | 2026-02-27 |
Family
ID=80952430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA69210A MA69210B1 (fr) | 2022-03-25 | 2023-03-27 | Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinine |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20250228782A1 (fr) |
| EP (2) | EP4499039B1 (fr) |
| JP (1) | JP2025510860A (fr) |
| KR (1) | KR20240161195A (fr) |
| CN (1) | CN119136786A (fr) |
| AU (1) | AU2023240388A1 (fr) |
| CA (1) | CA3250834A1 (fr) |
| CO (1) | CO2024012885A2 (fr) |
| DK (1) | DK4499039T3 (fr) |
| ES (1) | ES3062435T3 (fr) |
| FI (1) | FI4499039T3 (fr) |
| HR (1) | HRP20260203T1 (fr) |
| IL (1) | IL315700A (fr) |
| LT (1) | LT4499039T (fr) |
| MA (1) | MA69210B1 (fr) |
| MX (1) | MX2024011704A (fr) |
| PL (1) | PL4499039T3 (fr) |
| PT (1) | PT4499039T (fr) |
| RS (1) | RS67776B1 (fr) |
| SM (1) | SMT202600057T1 (fr) |
| TW (1) | TW202345810A (fr) |
| WO (1) | WO2023180576A1 (fr) |
| ZA (1) | ZA202408059B (fr) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0807105B1 (fr) | 1994-10-27 | 2004-06-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidones, quinoleines et heterocycles azotes fusionnes comme antagonistes de la bradykinine |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| WO1999064039A1 (fr) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Antagonistes de bradykinine |
| CA2347001A1 (fr) | 1998-10-21 | 2000-04-27 | Fujisawa Pharmaceutical Co., Ltd. | Forme vitreuse d'un antagoniste connu de bradykinine |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| CA2364178C (fr) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl-l-prolines utilisees comme antagonistes de la bradykinine |
| WO2003087090A2 (fr) | 2002-04-10 | 2003-10-23 | Ortho-Mcneil Pharmaceutical,Inc. | Nouveaux derives heteroarylalkylamide utiles en tant que modulateurs du recepteur de la bradykinine |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| CA2904052A1 (fr) | 2013-03-14 | 2014-10-02 | Shire Human Genetic Therapies, Inc. | Methodes de traitement de l'deme de quincke induit par le recepteur de la bradykinine du type b2 |
| WO2019101906A1 (fr) * | 2017-11-24 | 2019-05-31 | Pharvaris B.V. | Nouveaux antagonistes du récepteur b2 de la bradykinine |
| UY38707A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Nuevos antagonistas cíclicos del receptor b2 de bradiquinina |
| KR20230107269A (ko) * | 2020-11-12 | 2023-07-14 | 파르바리스 게엠베하 | 혈관부종의 예방 및 치료 |
-
2023
- 2023-03-25 TW TW112111337A patent/TW202345810A/zh unknown
- 2023-03-27 ES ES23715488T patent/ES3062435T3/es active Active
- 2023-03-27 FI FIEP23715488.5T patent/FI4499039T3/fi active
- 2023-03-27 JP JP2024556788A patent/JP2025510860A/ja active Pending
- 2023-03-27 DK DK23715488.5T patent/DK4499039T3/da active
- 2023-03-27 HR HRP20260203TT patent/HRP20260203T1/hr unknown
- 2023-03-27 PT PT237154885T patent/PT4499039T/pt unknown
- 2023-03-27 KR KR1020247035307A patent/KR20240161195A/ko active Pending
- 2023-03-27 RS RS20260209A patent/RS67776B1/sr unknown
- 2023-03-27 US US18/850,683 patent/US20250228782A1/en active Pending
- 2023-03-27 EP EP23715488.5A patent/EP4499039B1/fr active Active
- 2023-03-27 EP EP25219557.3A patent/EP4684830A3/fr active Pending
- 2023-03-27 SM SM20260057T patent/SMT202600057T1/it unknown
- 2023-03-27 LT LTEPPCT/EP2023/057792T patent/LT4499039T/lt unknown
- 2023-03-27 AU AU2023240388A patent/AU2023240388A1/en active Pending
- 2023-03-27 CN CN202380037796.5A patent/CN119136786A/zh active Pending
- 2023-03-27 CA CA3250834A patent/CA3250834A1/fr active Pending
- 2023-03-27 MA MA69210A patent/MA69210B1/fr unknown
- 2023-03-27 WO PCT/EP2023/057792 patent/WO2023180576A1/fr not_active Ceased
- 2023-03-27 PL PL23715488.5T patent/PL4499039T3/pl unknown
- 2023-03-27 IL IL315700A patent/IL315700A/en unknown
-
2024
- 2024-09-24 MX MX2024011704A patent/MX2024011704A/es unknown
- 2024-09-24 CO CONC2024/0012885A patent/CO2024012885A2/es unknown
- 2024-10-24 ZA ZA2024/08059A patent/ZA202408059B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024011704A (es) | 2024-11-08 |
| SMT202600057T1 (it) | 2026-03-09 |
| HRP20260203T1 (hr) | 2026-03-27 |
| US20250228782A1 (en) | 2025-07-17 |
| PL4499039T3 (pl) | 2026-03-30 |
| TW202345810A (zh) | 2023-12-01 |
| PT4499039T (pt) | 2026-02-17 |
| ES3062435T3 (en) | 2026-04-10 |
| EP4499039A1 (fr) | 2025-02-05 |
| DK4499039T3 (da) | 2026-02-16 |
| FI4499039T3 (fi) | 2026-02-05 |
| LT4499039T (lt) | 2026-02-25 |
| ZA202408059B (en) | 2026-01-28 |
| EP4499039B1 (fr) | 2025-12-03 |
| CN119136786A (zh) | 2024-12-13 |
| RS67776B1 (sr) | 2026-03-31 |
| KR20240161195A (ko) | 2024-11-12 |
| JP2025510860A (ja) | 2025-04-15 |
| AU2023240388A1 (en) | 2024-11-07 |
| EP4684830A3 (fr) | 2026-04-01 |
| EP4684830A2 (fr) | 2026-01-28 |
| CA3250834A1 (fr) | 2023-09-28 |
| WO2023180576A1 (fr) | 2023-09-28 |
| IL315700A (en) | 2024-11-01 |
| CO2024012885A2 (es) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11753399B2 (en) | Therapeutic compounds | |
| JP6356919B2 (ja) | Ｈｉｖの処置のためのイソキノリン化合物 | |
| JP6385584B2 (ja) | Ｈｉｖの処置のための縮合ピリミジン化合物 | |
| AU760735B2 (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
| JP5561720B2 (ja) | 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト／インバ−スアゴニスト | |
| TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
| DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
| HUP0302153A2 (hu) | Kemokin receptor aktívitás modulátoraiként hatásos piperidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| CN105793245B (zh) | 药物化合物 | |
| CN108602821A (zh) | 1h-咪唑并[4,5-b]吡啶基和2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶基杂环bet溴结构域抑制剂 | |
| TN2013000257A1 (en) | Immunosuppressant formulations | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| WO2014142607A1 (fr) | Médicament combiné pharmaceutique | |
| KR101354237B1 (ko) | 골수종 치료를 위한 ｈｄａｃ 저해제의 용도 | |
| MA69210B1 (fr) | Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinine | |
| ZA202408058B (en) | Solid composition comprising solubilised bradykinin b2-receptor antagonists | |
| JP2017537104A (ja) | 変形性関節症におけるσ受容体リガンドの使用 | |
| WO2016189406A1 (fr) | Composition pharmaceutique de tériflunomide | |
| EP3697754A1 (fr) | Dérivés de propanamine destinés au traitement de la douleur et des états pathologiques associés à la douleur | |
| US20100029775A1 (en) | Renin inhibitors for the prevention and treatment of hypertension in obese patients | |
| CN119654310A (zh) | 用于治疗胃肠和肺疾病的作为前列腺素e2受体4（ep4）激动剂的1,2-取代的3-氧代吡唑烷衍生物 | |
| HK1246776B (zh) | 用於hiv治疗的异喹啉化合物 | |
| EP1745782A1 (fr) | Utilisation de pyrazolines substituées pour la fabrication d' un médicament pour le traitement de la syndrome métabolique | |
| WO2007009694A1 (fr) | Utilisation de composes pyrazoliniques substitues pour l'elaboration de medicaments destines au traitement du syndrome metabolique |